Harmony Gold Mining Co. vs Eli Lilly And Co — how do they compare? Harmony Gold Mining Co. trades at $19.48 (market cap $12.24B), while Eli Lilly And Co trades at $1,220.55 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 88.2× Harmony Gold Mining Co.'s market cap, and Harmony Gold Mining Co. pays the higher dividend (2.09%). Which is the better fit depends on your goals.
| HMY | LLY | |
|---|---|---|
Market Cap | $12.24B | $1.08T |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $1.24K |
52-Week Low | $12.61 | $639.43 |
Enterprise Value | $12.58B | $1.13T |
Dividend Yield | 2.09% | 0.57% |
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $19.88, down 0.1% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong 2024 results with revenue of $61.38B and net income of $8.59B, supported by a strategic pivot to gold-copper production. Recent news highlights operational progress, including copper profit growth and diversification efforts.
HMY offers value with a P/E of 12.26 and robust profitability margins, but faces risks from gold price volatility and mixed analyst sentiment. The stock's outlook is supported by earnings growth and diversification, though investor caution is warranted due to Fed policy sensitivity and execution risks in expansion.
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
Trailing returns across standard periods
Latest headlines on both assets
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →